Related Experiment Video

Updated: Apr 6, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

"Braking" the Cycle of Resistance in Endocrine Therapy for Breast Cancer

Angela DeMichele1, Lewis A Chodosh2

  • 1Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 2-PREVENT Breast Cancer Translational Center of Excellence, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Angela.demichele@uphs.upenn.edu.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 24, 2015
PubMed

Insights

Endocrine resistance in breast cancer can cause recurrence. Animal models help identify new therapies targeting estrogen receptor activity and the cell cycle with CDK4/6 inhibitors.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Endocrine resistance is a major cause of breast cancer recurrence and mortality.
  • Animal models are crucial for preclinical testing of therapeutic strategies against endocrine resistance.
  • Understanding resistance mechanisms is key to developing effective treatments.

Purpose of the Study:

  • To investigate the interplay between estrogen receptor (ESR-1) activity and cell cycle progression in endocrine-resistant breast cancer.
  • To evaluate the efficacy of targeting these interactions using CDK4/6 inhibitors in preclinical models.
  • To gain insights into novel therapeutic combinations for overcoming endocrine resistance.

Main Methods:

  • Utilized animal models of endocrine-resistant breast cancer.
  • Examined the effects of CDK4/6 inhibitors on estrogen receptor (ESR-1) activity.
  • Assessed the impact on cell cycle regulation in the context of resistance.

Main Results:

  • The study provides new insights into targeting the interaction between ESR-1 activity and the cell cycle.
  • CDK4/6 inhibitors show potential in preclinical models of endocrine resistance.
  • This approach offers a strategy for optimally targeting resistance mechanisms.

Conclusions:

  • Animal models are valuable for studying endocrine resistance in breast cancer.
  • Targeting the cell cycle in conjunction with estrogen receptor activity may overcome resistance.
  • CDK4/6 inhibitors represent a promising therapeutic avenue for endocrine-resistant breast cancer.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer10:36

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

11.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.3K